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Abstract
Background: Ingestion of the poisonous weed ragwort (Senecio jacobea) by horses leads to
irreversible liver damage. The principal toxins of ragwort are the pyrrolizidine alkaloids that are
rapidly metabolised to highly reactive and cytotoxic pyrroles, which can escape into the circulation
and bind to proteins. In this study a non-invasive in vitro model system has been developed to
investigate whether pyrrole toxins induce specific modifications of equine blood proteins that are
detectable by proteomic methods.
Results: One dimensional gel electrophoresis revealed a significant alteration in the equine plasma
protein profile following pyrrole exposure and the formation of a high molecular weight protein
aggregate. Using mass spectrometry and confirmation by western blotting the major components
of this aggregate were identified as fibrinogen, serum albumin and transferrin.
Conclusion: These findings demonstrate that pyrrolic metabolites can modify equine plasma
proteins. The high molecular weight aggregate may result from extensive inter- and intra-molecular
cross-linking of fibrinogen with the pyrrole. This model has the potential to form the basis of a
novel proteomic strategy aimed at identifying surrogate protein biomarkers of ragwort exposure
in horses and other livestock.
Background
Ragwort (Senecio jacobea) is a poisonous weed found
growing on riverbanks, roadsides and pasture and is toxic
to most grazing livestock. Horses are particularly sensitive
to the toxic effects of ragwort and typically avoid the weed,
but poisoning can occur when the animals graze on
poorly maintained pastures or when feedstuff such as hay
or silage is contaminated. Ragwort poisoning leads to
complete liver failure, however the clinical signs can be
slow to develop and may only manifest after prolonged
dietary exposure. Prognosis is poor once the liver disease
is advanced and current treatments are only palliative [1].
The early diagnosis of ragwort poisoning is extremely dif-
ficult as many conventional biochemical and histopatho-
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logical indicators of the disease are non-specific and do
not discriminate ragwort poisoning from other immune,
infectious or toxic diseases [2].
The toxic precursors in ragwort are pyrrolizidine alkaloids
[3-5]. Amongst the most prominent pyrrolizidine alka-
loids found in ragwort are jacobine, erucifoline and sene-
cionine [6,7]. Following ingestion of ragwort the
pyrrolizidine alkaloids are absorbed from the gastrointes-
tinal tract and pass to the liver where they can be rapidly
metabolised by the cytochrome P450 system to reactive
and cytotoxic pyrroles [8,9] (Figure 1). The pyrrolic
metabolites bind to liver macromolecules such as DNA,
eliciting cell injury [10,11] but they can also escape into
the circulation where they react with the thiol groups of
cysteine residues of blood proteins [12,13]. The persist-
ence of these adducts formed the basis of one chemical
analysis that was developed over a decade ago [14,15]. In
this test, haemoglobin thioesters were treated with eth-
anolic silver nitrate under acidic conditions, releasing a
diethoxyether form of the bound pyrrole that can be iden-
tified by thin-layer chromatography, gas chromatography
or high performance liquid chromatography. This
approach has been used to confirm ragwort poisoning in
horses [16], cattle [17] and yaks [18] but has not been
adopted widely.
An alternative strategy might be to directly analyse pyr-
role-protein complexes in blood rather than by the recov-
ery of the xenobiotics. In this study an in vitro model
system has been developed to investigate whether pyrrole
toxins induce specific modifications of equine blood pro-
teins that are detectable by proteomic methods. Such an
approach may identify target proteins that could serve as
surrogate markers of ragwort exposure. It offers the possi-
bility of a novel analytical strategy to improve the diagno-
sis of ragwort toxicity in horses and other livestock.
Results and discussion
Ethical considerations preclude toxicological studies that
would require horses to be exposed to ragwort. Therefore,
an in vitro model system was developed to determine the
modifications to horse blood proteins induced by the
toxic metabolites of ragwort. Commercial preparations of
the major pyrrolizidine alkaloids from ragwort are expen-
sive and therefore a structurally and chemically related
pyrrolizidine alkaloid, monocrotaline, was used to opti-
mise methodologies. The model involved the chemical
oxidation of monocrotaline to its pyrrolic derivative,
dehydromonocrotaline (DHM), followed by modifica-
tion of horse proteins obtained from surplus clinical
blood samples taken for diagnostic purposes. Proteomic
methods were then used to detect specific alterations of
the equine blood proteins.
Pyrrole modification of equine haemoglobin
Pyrrole thioesters of haemoglobin are believed to be rela-
tively stable [12-14] and may remain in the bloodstream
for the lifespan of the erythrocyte (approximately four
months in the horse). The detection of pyrrole-modified
haemoglobin molecules could act as an indicator of rag-
wort exposure over a prolonged period. Equine haemo-
globin, prepared from freshly collected blood, was
incubated in vitro with varying concentrations of synthe-
sised DHM and analysed for evidence of pyrrole modifica-
tion. 1-D SDS-PAGE showed no changes in the profile of
Chemical structure of pyrrolizidine alkaloids Figure 1
Chemical structure of pyrrolizidine alkaloids. Jacobine is one of the major pyrrolizidine alkaloids found in ragwort. The 
related pyrrolizidine alkaloid, monocrotaline was used in the experimental procedures of this study. Monocrotaline was chem-
ically oxidised to its pyrrolic derivative, dehydromonocrotaline (DHM) and exposed to equine plasma proteins.
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the haemoglobin following pyrrole exposure and simply
separated the α- and β-chains. This approach was unlikely
to provide sufficient resolution to discriminate between
modified and non-modified haemoglobin molecules if a
single cysteine residue had been adducted. The haemo-
globin molecule was further analysed by intact protein
mass spectrometry. Free cysteine and cysteine-containing
peptides such as glutathione are readily modified by pyr-
rolic metabolites [19-21]. The adduction of a pyrrole to a
cysteine residue would be expected to increase the molec-
ular weight of each haemoglobin chain by either 117 or
135 Da, depending on whether the pyrrole moiety dehy-
drates. Intact mass analysis of the haemoglobin using
electrospray ionisation-mass spectrometry (ESI-MS)
revealed two peaks at 15,114 ± 2 Da and 16,008 +/- 2 Da,
which corresponded to the predicted molecular weights of
the α- and β-chains respectively. An additional peak at
15,098 +/- 2 Da was due to a Phe24→Tyr24 variant of the
α-chain equine haemoglobin, whilst a peak detected at
16,313 +/- 2 Da was attributed to the glutathionylated
form of the β-chain, indicating that the cysteine residue
was accessible in a significant proportion of the β-chain.
The haemoglobin was also digested with trypsin and the
resultant peptides were analysed by matrix assisted laser
desorption ionisation-time-of-flight-mass spectrometry
(MALDI-ToF-MS). Despite 90% sequence coverage of
each of the globin chains, the analysis failed to reveal any
pyrrole modification of the cysteine containing peptide.
The inability to detect pyrrole adducts may be due to a
combination of factors. The pyrrole modification may be
spread over the α- and β-chains of haemoglobin and it is
possible that the extent of modification of haemoglobin is
too low to be observed in the predominant unmodified
haemoglobin pool. It is also possible that glutathione in
the erythrocytes may have protected the haemoglobin
from pyrrole modification, however glutathione-pyrrole
adducts were not detected in blood samples by mass spec-
trometric analysis. In addition, there may be difficulties in
reacting pyrroles with intact equine haemoglobin. The α-
chain cysteine residue of horse haemoglobin is situated in
a relatively hydrophobic region of the protein, which is
likely to render it inaccessible to pyrrole metabolites.
However, the β-chain cysteine at position 93 is more
externally located and is more susceptible to modification
[22,23]. This conjecture was confirmed when equine hae-
moglobin was modified with the pyrrole under reducing
and denaturing conditions and a small amount of β-chain
adduction was detected by intact mass analysis using ESI-
MS.
Pyrrole modification of equine plasma proteins
Other potential protein targets of pyrrole modification in
horse blood were also investigated. As the first site of
exposure to pyrroles would be plasma proteins, equine
plasma was incubated with chemically synthesised DHM
and the proteins analysed by 1-D SDS-PAGE. Both non-
reducing and reducing gels revealed a significant altera-
tion in the equine plasma protein profile following pyr-
role exposure (Figure 2). There was a shift in mobility of a
number of protein bands and a protein aggregate was
detected in the high molecular weight region of the resolv-
ing gel, which became more pronounced with increasing
concentrations of DHM. The aggregate was not observed
in control samples where plasma was treated with a reac-
tion mixture that was complete apart from DHM. Simi-
larly, controls where monocrotaline or the carrier solvent,
N,N-dimethylformamide (DMF), was exposed to plasma
also failed to produce any changes in the protein profile.
Modification was therefore caused by the presence of pyr-
role in the experimental system. DHM is capable of cross-
linking proteins [24,25]. The proteins in the high molec-
ular weight aggregate at the top of the gel were identified
using liquid chromatography-tandem mass spectrometry
(LC-MS/MS). The major components of the aggregate
were identified with high confidence (p ≤ 0.05) as serum
albumin, fibrinogen, transferrin and immunoglobulin
gamma (IgG) (Tables 1 and 2).
Due to the evidence of cross-linking of the major plasma
proteins authentic standards of serum albumin, fibrino-
gen and transferrin were reacted with DHM. As equine
protein standards were not available from commercial
sources bovine standards were used in their place. Fibrin-
ogen appeared to be particularly susceptible to modifica-
tion by the pyrrole, being substantially converted to a
high molecular weight aggregate. In contrast, the bovine
serum albumin and transferrin standards displayed only
limited reactivity with DHM and did not show the same
shift in mobility corresponding to the high molecular
weight aggregate. It was possible that the presence of IgG,
albumin and transferrin in whole plasma was due to co-
polymerisation and aggregation with the fibrinogen mol-
ecule.
Since fibrinogen was reactive with DHM dose-response
and time-course experiments were conducted. The opti-
mal concentration for pyrrole exposure was calculated at
a molar ratio of DHM:protein of 10:1 (Figure 3). Lower
concentrations of the pyrrole failed to completely modify
the protein, whereas high concentrations resulted in
instantaneous and complete modification. Figure 4 shows
1-D SDS-PAGE analysis of pyrrole-treated fibrinogen over
a 120 min incubation period. The density of the fibrino-
gen bands, and in particular the α-chain, diminished over
time, suggesting that the protein is gradually modified in
a way which prevents it from entering the gel and migrat-
ing to its usual position. This correlates well with the
appearance of high molecular weight aggregates.BMC Veterinary Research 2008, 4:30 http://www.biomedcentral.com/1746-6148/4/30
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All of the cysteine residues in fibrinogen maintain the ter-
tiary structure of the protein through disulphide bonds. In
principle these oxidised cysteines residues would not be
available to react with an alkylating agent such as pyrrole,
and modification of amino acid residues other than
cysteine may have occurred. Tentative identifications of
pyrrole modified peptides were made from MALDI-ToF-
MS analysis of in-gel and in-solution tryptic digests of the
fibrinogen aggregate, however, additional mass spectro-
metric analysis using LC-MS/MS was unable to confirm
the site pyrrole modification. This may occur due to the
fact that the covalent linkage between the pyrrole and
amino acid residues may not be stable to conditions of
analysis by mass spectrometry [26,27]. The formation of
specific pyrrole derived fragment ions can vary depending
on the amino acid adducted and the surrounding peptide
sequence. Pyrrole modification also disrupts the normal
peptide fragmentation [28] complicating the ability to
obtain sequence information from modified peptides.
Western blotting of pyrrole modified plasma proteins
In order to further investigate the response of plasma pro-
teins with DHM, western blots were performed using anti-
bodies to equine fibrinogen. After exposure to DHM, the
fibrinogen α-chain band was no longer observed. Western
blots using antibodies to equine serum albumin and
transferrin indicated that albumin was modified to a
lesser extent following DHM exposure, whereas the trans-
ferrin demonstrated no reactivity with pyrrole. A dose-
response study revealed that the fibrinogen aggregation is
initiated when an approximate sixty-fold molar excess of
pyrrole is added to plasma (Figure 5).
Conclusion
Although ragwort poisoning is recognised as a threat to
equidae, the true extent of this threat cannot be assessed
in the absence of a definitive and specific test for exposure
to the toxin. At present, clinical tests are focused on a
more generalised manifestation of hepatic damage. The
The effect of pyrrole exposure on equine plasma protein profile Figure 2
The effect of pyrrole exposure on equine plasma protein profile. Equine plasma was reacted with 10–100 molar 
excess of DHM for 60 min at room temperature. Control horse plasma was treated with a reaction mixture that was complete 
apart from DHM. Proteins were separated by 1-D SDS-PAGE on 7.5% (w/v) gels under (A) non-reducing and (B) reducing con-
ditions. Gels were stained with Coomassie brilliant blue. High molecular weight aggregates are evident in pyrrole treated lanes 
from both gels. Proteins identifications are detailed in Tables 1 and 2.
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Table 1: Identification of proteins from equine plasma in non-reducing 1-D SDS-PAGE. The plasma proteins were identified using LC-
MS/MS. 
Band No. Protein Identification Accession No. Mr (kDa) pI MOWSE Score a 
(p ≤ 0.05)
No. of Peptides 
Matched
% Coverageb Species
NR1 Serum albumin CAA52194 70.6 5.95 403 (44) 41 34 Equus caballus
Fibrinogen A α chain 
(fragment)
AAC67561 49.6 6.45 138 (44) 11 7 Equus caballus
Immunoglobulin gamma 4 
heavy chain constant region 
(fragment)
CAC44763 37.0 8.04 147 (44) 15 20 Equus caballus
Immunoglobulin gamma 7 
heavy chain
AAS18414 36.3 7.70 109 (44) 13 - Equus caballus
Immunoglobulin gamma 4 
heavy chain
AAS18415 36.2 7.71 106 (44) 15 - Equus caballus
Transferrin AAA63684 80.3 6.83 102 (44) 5 6 Equus caballus
NR2 Serum albumin CAA52194 70.6 5.95 477 (45) 34 41 Equus caballus
Immunoglobulin mu AAU09792 50.1 5.52 372 (45) 24 44 Equus caballus
Lambda immunoglobulin 
(fragment)
AAA50978 17.7 8.35 165 (45) 9 31 Equus caballus
Fibronectin AAC48614 58.1 5.91 124 (45) 3 7 Equus caballus
NR3 Fibrinogen A α chain 
(fragment)
AAC67561 49.6 6.45 754 (44) 42 45 Equus caballus
Serum albumin CAA52194 68.6 5.95 265 (44) 22 24 Equus caballus
Fibrinogen γ B chain CAA33562 50.8 5.54 121 (44) 6 6 Bos taurus
NR4 Lamba Immunoglobulin 
(fragment)
AAA50978 17.4 8.35 274 (44) 15 32 Equus caballus
Immunoglobulin gamma 5 
heavy chain constant region 
(fragment)
CAC86340 35.9 5.95 272 (44) 20 28 Equus caballus
Immunoglobulin gamma 1 
heavy chain constant region 
(fragment)
CAC44624 37.4 7.68 270 (44) 7 17 Equus caballus
Serum albumin CAA52194 68.6 5.95 265 (44) 22 24 Equus caballus
NR5 Immunoglobulin gamma 1 
heavy chain constant region 
(fragment)
CAC44624 37.4 7.68 554 (44) 26 34 Equus caballus
Immunoglobulin G heavy 
chain (fragment)
AAG01011 47.6 5.70 411 (44) 30 27 Equus caballus
NR6 Serum albumin CAA52194 70.6 5.95 717 (44) 59 48 Equus caballus
Immunoglobulin gamma 4 
heavy chain
AAS18415 36.2 7.71 463 (44) 59 - Equus caballus
Immunoglobulin gamma 7 
heavy chain
AAS18414 36.3 7.70 454 (44) 56 - Equus caballus
Immunoglobulin gamma 4 
heavy chain constant region 
(fragment)
CAC44763 37.0 8.04 374 (44) 46 37 Equus caballus
Lambda immunoglobulin 
(fragment)
AAA50978 7.7 8.35 337(44) 52 - Equus caballus
NR7 Gelsolin Q28372 80.9 5.58 354(44) 15 20 Equus caballus
NR8 Transferrin AAA63684 80.3 6.83 421 (44) 31 27 Equus caballus
Carboxylesterase 1 AAH21150 63.0 5.64 114 (44) 6 6 Mus musculus
NR9 Transferrin AAA63684 80.3 6.83 665 (44) 51 32 Equus caballus
α-1-antitrypsin AAC83412 47.1 5.23 150 (44) 7 8 Equus caballus
Serum albumin AAV28861 70.5 5.89 95 (44) 8 12 Equus asinus
Proteins were identified on the basis of their MOWSE score using the MSDB database. Each band number refers to proteins identified in Figure 2A. a = 
MOWSE baseline significance score in brackets; b = for those with no percentage coverage value the database did not give this information.BMC Veterinary Research 2008, 4:30 http://www.biomedcentral.com/1746-6148/4/30
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poisoning is chronic and accumulative, and the emer-
gence of symptoms may post date the exposure to the
plant by weeks or even months. There is therefore a press-
ing need for a test that can assess the history of exposure.
The most successful test used previously was based on
qualitative assessment of adducts of the pyrrole with
blood proteins [14,15]. Accordingly, an in vitro model sys-
tem, not requiring deliberate exposure of horses to pyr-
rolizidine alkaloids, was developed to explore the
specificity of adduction. Perhaps surprisingly, the highly
abundant haemoglobin chains were not modified, which
might reflect lack of availability of reactive side chains, or
the inability of the pyrrole to survive for long enough in
plasma to cross the erythrocyte membrane. Plasma pro-
teins might therefore be targets for pyrrole modification,
and the discovery that fibrinogen was modified is the first
step towards such a specific test.
It is not known whether a protein-based analysis is more
sensitive than a test based on measurement of pyrrole res-
idues after release from proteins, or indeed, is sensitive
enough for a routine analysis. However, the mass-shifted
modification of fibrinogen chains is easily detected by
western blotting, and could be readily performed in many
laboratories, requiring minimal investment in equipment
and using a commercially available antiserum. Because
the test is based on a mass shift, a simple ELISA cannot be
substituted, as this would not discriminate between the
unmodified and modified fibrinogen chains. Deployment
of this simple assessment may be of greatest value in iden-
tifying and establishing a pool of cases that can then be
used to develop even more sensitive test, based on specific
peptide modification or on direct detection of pyrrole
moieties in a blood sample. Such a screening test may
enable veterinarians to identify ragwort exposure and
would therefore be an invaluable diagnostic tool with
substantial welfare benefits.
Methods
Experimental samples
Whole blood was collected into lithium heparin tubes
from horses by venepuncture as part of routine clinical
investigations. Any surplus blood (approximately 10 mL)
was used in this study. The blood was spun at 1,300 × g
for 10 min and the plasma removed. Erythrocytes were
then washed three times with isotonic phosphate buffered
saline (10 mM phosphate, 140 mM NaCl, 2.6 mM KCl,
pH 7.4) and lysed by adding five volumes of distilled
water. Erythrocyte membranes were removed by centri-
fuging the haemolysate at 18,000 × g for 20 min.
Ethical statement: The study was performed in adherence
to the University of Liverpool Animal Ethics Guidelines.
Chemical synthesis of DHM
DHM was synthesised by the chemical oxidation of
monocrotaline [29,30]. Monocrotaline (10 mg, Sigma,
Poole, UK) dissolved in 2 mL chloroform was added to 21
mg tetrabromo-1,2-benzoquinone (o-bromanil) (Sigma)
dissolved in 2 mL chloroform and stirred for 2 min at
room temperature. A mixture of sodium borohydride (3
mg) and sodium hydroxide (700 mg) dissolved in 2 mL
distilled water was added to quench the reaction, resulting
in a green precipitate. The lower organic layer was imme-
diately collected, dried over anhydrous sodium sulphate,
filtered through decolorising charcoal and concentrated
to dryness under nitrogen gas. The DHM was then redis-
solved in DMF and used immediately. The approximate
yield of DHM was 95–100%.
Reaction of pyrrole with proteins
The protein concentration of haemoglobin and plasma
was determined using the Coomassie Plus Protein Assay
(Pierce Biotechnology, Rockford, USA). To haemoglobin
lysate (approximately 25 mg) or plasma (approximately
10 mg), DHM dissolved in DMF was added in molar
ratios of between 1:1 and 100:1 DHM:protein. This was
left mixing at room temperature for 60 min. Bovine fibrin-
ogen, serum albumin and transferrin protein standards
(Sigma) were dissolved at 1 mg/mL in 50 mM ammonium
bicarbonate. DHM was added to a final molar ratio of
10:1 DHM:protein and left to react at room temperature
for up to 120 min. The reaction of pyrrole with protein
was halted at each time point by addition of an equal vol-
ume of 1 mg/mL glutathione in 50 mM ammonium bicar-
bonate. Multiple control plasma samples were analysed as
follows: plasma treated with the reaction mixture without
DHM; plasma treated with monocrotaline alone; and
plasma treated with the carrier solvent, DMF. The approx-
imate molecular weight used for calculating the molar
ratios of DHM incubations of complete plasma was 55
kDa. Replicate experiments were performed on five sepa-
rate occasions.
1-D SDS-PAGE
Plasma samples and protein standards (10 μg) were
resolved at a constant potential of 200V through either 7.5
or 12.5% (w/v) polyacrylamide gels with 4% (w/v) stack-
ing gel. The samples were boiled at 100°C for 5 min in a
reducing buffer (125 mM Tris-HCl; 140 mM SDS; 20% (v/
v) glycerol; 200 mM dithiothreitol (DTT) and 30 mM
bromophenol blue) or left at room temperature for 5 min
in a non-reducing buffer (as for reducing buffer minus
DTT) prior to loading. Gels were stained with Coomassie
brilliant blue (Amersham Biosciences, Buckinghamshire,
UK).BMC Veterinary Research 2008, 4:30 http://www.biomedcentral.com/1746-6148/4/30
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Table 2: Identification of proteins from equine plasma in reducing 1-D SDS-PAGE. 
Band No. Protein Identification Accession No. Mr (kDa) pI MOWSE Scorea 
(p≤ 0.05)
No. of Peptides 
Matched
% Coverageb Species
R1 Serum albumin CAA52194 70.5 5.95 437 (44) 48 30 Equus caballus
Immunoglobulin gamma 7 
heavy chain
AAS18414 36.3 7.70 132 (44) 8 - Equus caballus
Immunoglobulin gamma 4 
heavy chain
AAS18415 36.2 7.71 127 (44) 10 - Equus caballus
Fibrinogen A α chain 
(fragment)
AAC67561 49.6 6.45 49 (45) 3 7 Equus caballus
R2 Serum albumin CAA52194 70.6 5.95 639 (44) 39 31 Equus caballus
Fibrinogen A α chain 
(fragment)
AAC67561 49.6 6.45 230 (44) 14 19 Equus caballus
Immunoglobulin G heavy 
chain (fragment)
AAG01011 47.6 5.7 141 (44) 8 14 Equus caballus
Immunoglobulin G light 
chain (fragment)
AAG01010 24.5 6.4 141 (44) 4 9 Equus caballus
Apolipoprotein A-1 P02648 30.2 5.2 94 (44) 6 7 Canis familiaris
R3 Transferrin AAA63684 80.3 6.83 685 (44) 47 32 Equus caballus
Fibrinogen A α chain AAC67561 49.6 6.45 195 (44) 15 26 Equus caballus
Serum albumin CAA52194 70.6 5.95 187 (44) 16 14 Equus caballus
Immunoglobulin mu AAU09792 50.1 5.52 127 (44) 10 16 Equus caballus
R4 Serum albumin AAV28861 70.5 5.89 249 (45) 18 16 Equus caballus
Fibrinogen A α chain AAC67561 49.6 6.45 50 (45) 3 5 Equus caballus
R5 Immunoglobulin gamma 7 
heavy chain
AAS18414 36.3 7.7 305 (44) 25 Equus caballus
Immunoglobulin gamma 4 
heavy chain constant 
region (fragment)
CAC44763 37.0 8.04 280 (44) 24 32 Equus caballus
Immunoglobulin gamma 5 
heavy chain constant 
region (fragment)
CAC86340 36.4 5.95 256 (44) 24 33 Equus caballus
Immunoglobulin G heavy 
chain (fragment)
AAG01011 47.6 5.7 256 (44) 22 21 Equus caballus
Immunoglobulin gamma 4 
heavy chain
AAS18415 36.2 7.71 247 (44) 24 - Equus caballus
Immunoglobulin gamma 1 
heavy chain constant 
region (fragment)
CAC44624 38.0 7.68 224 (44) 11 19 Equus caballus
Immunoglobulin gamma 6 
heavy chain constant 
region (fragment)
CAC86341 36.5 8.03 212 (44) 13 24 Equus caballus
Serum albumin CAA52194 70.6 5.95 92 (44) 6 4 Equus caballus
Haptoglobin CAA25267 39.0 6.13 75 (45) 5 - Homo sapiens
R6 Immunoglobulin gamma 7 
heavy chain
AAS18414 36.3 7.7 305 (44) 25 Equus caballus
Immunoglobulin gamma 4 
heavy chain constant 
region (fragment)
CAC44763 37.0 7.28 280 (44) 24 32 Equus caballus
Immunoglobulin gamma 4 
heavy chain
AAS18415 36.2 7.71 247 (44) 24 -
Immunoglobulin gamma 1 
heavy chain constant 
region (fragment)
CAC44624 38.0 7.68 224 (44) 11 19 Equus caballus
Immunoglobulin gamma 6 
heavy chain constant 
region (fragment)
CAC86341 36.5 8.03 212 (44) 13 24 Equus caballusBMC Veterinary Research 2008, 4:30 http://www.biomedcentral.com/1746-6148/4/30
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Digestion of proteins with trypsin
Gel plugs from protein bands of interest were excised and
the proteins were destained by repeated incubation in a
solution of 50 mM ammonium bicarbonate in 50% (v/v)
acetonitrile at 37°C for 20 min. When preparing samples
for the detection of pyrrole modifications the gel plugs
were dehydrated with acetonitrile and allowed to air dry.
For protein identification, the plugs were additionally
washed in 50 mM ammonium bicarbonate and incubated
in 10 mM DTT at 37°C. After 30 min the supernatant was
discarded, 55 mM iodoacetamide was added and the incu-
bation was continued in the dark for 60 min. In all cases,
gel plugs were digested with 10 μL of trypsin (10 ng/μL)
in 50 mM ammonium bicarbonate. In-solution digestion
of protein samples was performed in 50 mM ammonium
bicarbonate with trypsin (10 μg/μL) at a ratio of pro-
tein:trypsin 50:1.
Intact mass analysis by ESI-MS
Intact mass analysis of haemoglobin was performed using
ESI-MS on a Q-ToF Micro tandem mass spectrometer
(Waters, Manchester, UK), equipped with a nanospray
source. All analyses were performed in positive ion mode.
Proteins were diluted to a concentration of 1 μM with ace-
tonitrile/water (50/50, v/v) containing 0.1% (v/v) formic
acid and directly infused into the ESI source at a flow rate
of 0.5 μL/min. Data were acquired between m/z  500–
2000. Typically 20 scans were combined into a single
spectrum, which was subsequently deconvoluted using
MaxENT 1 maximum entropy software (Waters). Mass
spectra were processed between 15,000 and 17,000 Da at
1 Da/channel.
Peptide mass fingerprinting by MALDI-ToF-MS
Peptide analysis of protein (haemoglobin) digestion
products was performed in positive ion mode on a
M@LDI R mass spectrometer (Waters, Manchester, UK).
The instrument was calibrated for each batch of analysis
using a standard mix containing des-arg bradykinin (Mr
903.47), neurotensin (Mr 1671.92), adrenocorticotrophic
hormone (Mr 2464.20) and insulin-β chain (Mr 3493.65).
All standards were purchased from Sigma (Poole, UK).
R7 Immunoglobulin gamma 4 
heavy chain
AAS18415 36.2 7.71 93 (44) 3 10 Equus caballus
Immunoglobulin gamma 4 
heavy chain constant 
region (fragment)
CAC44763 37.0 7.28 93 (44) 3 10 Equus caballus
R8 Apolipoprotein A-1 P02648 30.1 5.2 608 (44) 36 27 Canis familiaris
Lambda immunoglobulin 
(fragment)
AAA50978 17.6 8.35 295 (44) 17 23 Equus caballus
Lambda immunoglobulin 
(fragment)
AAA50971 20.7 8.22 192 (44) 7 24 Equus caballus
The plasma proteins were identified using LC-MS/MS. Proteins were identified on the basis of their MOWSE score using the MSDB database. Each 
band number refers to proteins identified in Figure 2B. a = MOWSE baseline significance score in brackets; b = for those with no percentage 
coverage value the database did not give this information.
Table 2: Identification of proteins from equine plasma in reducing 1-D SDS-PAGE.  (Continued)
The effect of pyrrole concentration on fibrinogen standard Figure 3
The effect of pyrrole concentration on fibrinogen standard. Varying concentrations of DHM were incubated with a 
bovine fibrinogen standard, which was then analysed using reducing 1-D SDS-PAGE for 120 mins at room temperature. The 
proteins were separated on 7.5% (w/v) gels and visualised with Coomassie brilliant blue. Higher concentrations of DHM caused 
the modification of fibrinogen, whereas lower concentrations showed no effect. The α- β- and γ-chains of bovine fibrinogen are 
labelled. Key: - = control reaction mixture complete apart from DHM; + = reaction mixture containing DHM.
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Samples were mixed 1:1 with a saturated solution of α-
cyano-4-hydroxy cinnamic acid in 50% v/v ACN 0.1% v/
v trifluroacetic acid and 2 μL of the resultant mixture were
spotted onto a MALDI target. MALDI spectra were
acquired over the m/z  range 800–4000. Proteins were
identified from their peptide mass fingerprints by manual
searching using a locally implemented MASCOT server
version 1.9 http://www.matrixscience.com against the
MSDB and SWISS-PROT databases. Initial search parame-
ters allowed a mass tolerance of ± 250 ppm, a variable
trypsin missed cleavage, carbamidomethyl modification
of cysteine residues and variable oxidation of methionine.
The taxonomic search space was restricted to Chordata.
LC-MS/MS analysis
Plasma proteins were identified by LC-MS/MS analysis of
peptide digests using an LTQ ion-trap mass spectrometer
(Thermo-Electron, Hemel Hempstead, UK) equipped
with a nanospray electrospray ionisation source coupled
to a Ultimate 3000 nanoLC system (Dionex, Camberley,
UK). The LTQ was calibrated using a 500 fmol/μL solu-
tion of human [Glu1]-fibropeptide B (Mr 1570.62). The
samples were initially desalted and concentrated on a C18
PepMap pre-column (5 mm × 300 μm i.d.) (Dionex) prior
to separation on a C18 PepMap column (15 cm × 75 μm
i.d.) (Dionex). The column was equilibrated in 0.1% (v/
v) formic acid (FA) at a flow rate of 0.3 μl/min. Peptides
(20 μL) were then loaded and washed for 5 min at the
same flow rate prior to being eluted with a linear gradient
of 0–100% (v/v) acetonitrile/0.1% (v/v) FA over 50 min
at a flow rate of 0.2 μL/min. All analyses were in positive
ion mode. MS/MS spectra were acquired in the data
dependant mode. Doubly or triply charged peptide ions
were identified from a survey scan (m/z 400–1500), fol-
lowing which the top three individual precursor ions were
automatically selected for fragmentation using the "triple-
play" mode. The spectral data were converted to DTA files
using the SEQUEST search engine. The merged DTA files
were then used to search a locally implemented MASCOT
server version 1.9 against the MSDB databases. Search
parameters allowed a peptide tolerance of ± 200 ppm,
Time-course of pyrrole modification of fibrinogen standard Figure 4
Time-course of pyrrole modification of fibrinogen standard. DHM was added to a bovine fibrinogen standard at a 10 
molar excess. Aliquots were taken between 0 and 120 min post pyrrole addition and analysed by 1-D SDS-PAGE. Protein sam-
ples were mixed with reducing sample buffer and analysed on a 7.5% (w/v) gel. The gel was stained with Coomassie brilliant 
blue. From 30 min onwards the density of the fibrinogen bands, in particular the α-chain, appear to be diminished after reaction 
with the pyrrole. Key: - = control reaction mixture complete apart from DHM; + = reaction mixture containing DHM.
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Monitoring the effect of pyrrole exposure on equine plasma  fibrinogen using western blotting Figure 5
Monitoring the effect of pyrrole exposure on equine 
plasma fibrinogen using western blotting. Equine 
plasma was reacted with varying concentrations of DHM for 
60 min at room temperature. Control plasma was treated 
with a reaction mixture that was complete apart from DHM. 
Samples were analysed by 1-D SDS-PAGE and proteins were 
blotted onto nitrocellulose membranes and blocked over-
night before probing with an anti-equine fibrinogen antibody. 
Blots were then incubated with an alkaline phosphatase 
linked secondary antibody and developed. Migration of fibrin-
ogen α-chain was evident following the exposure of a large 
excess of pyrrole.
DHM:Protein Molar Ratio Control
8:1 32:1 16:1 64:1
DHM:Protein Molar Ratio
3:1 1:1
Control
200kDa
66 2kDa
97.4 kDa
116kDa
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MS/MS tolerance of ± 0.8 Da, up to one missed trypsin
cleavage and with carbamidomethylation of cysteine resi-
dues and oxidation of methionine as variable modifica-
tions. The taxonomic search space was restricted to
Chordata.
Western blotting
The identity of proteins was confirmed using western blot-
ting. Equine plasma was incubated with DHM as
described above and the proteins were separated using 1-
D SDS-PAGE. The proteins were transferred to a 0.2 μm
nitrocellulose membrane (Schleicher & Schuell, Dassel,
Germany) at 200 mA for 120 min. The blot was probed
with a 1:50,000 dilution of rabbit (polyclonal) anti-
(equine) fibrinogen (Affiland, Belgium) for 120 min at
room temperature. To detect transferrin and albumin in
equine plasma rabbit anti-equine transferrin and rabbit
anti-equine albumin antibodies (Bethyl Laboratories,
Cambridge, UK) were used respectively. Each blot was
incubated for 60 min with a 1:5000 dilution of goat anti-
rabbit IgG (whole molecule) alkaline phosphatase-conju-
gated secondary antibody (Sigma). The blot was devel-
oped with 5-bromo-4-chloro-3-indolyl phosphate/nitro
blue tetrazolium until colour developed, after which the
substrate was decanted and the blots rinsed with water.
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